TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03201133

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular evaluation
Description: (1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
Study: NCT00654056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
Study: NCT02865278

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard meal
Description: The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal
Description: The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
Study: NCT01920516

Intervention type: DRUG
Intervention: Melphalan
Description: Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
Study: NCT00180167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: randomization between two established Chemotherapies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: randomization between two established Chemotherapies
Study: NCT01537146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Bolus infusion via catheter/6H for 24H

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
Study: NCT01708447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L.M.X.4.® cream
Description: A lidocaine topical anesthetic cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A placebo cream
Description: Placebo cream containing no anesthetic properties.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT01951703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Control, senfilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Test, senofilcon A
Study: NCT00005799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo low-dose TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo nonmyeloablative allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo DLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01157195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-AutoCITE
Description: Automated, remotely-administered form of CI therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CI therapy
Description: CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
Study: NCT01566461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Description: Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Balloon: Balloon Angioplasty
Description: Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
Study: NCT00704561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)
Description: ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
Study: NCT00955942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: Given orally
Study: NCT02832128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00063
Description: 4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
Study: NCT00704561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)
Description: DRIVER bare metal stent implanted in acute myocardial infarction
Study: NCT03583086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV
Study: NCT00704561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent implantation
Description: Comparison of Drug Eluting versus Bare Metal Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Coronary Stent
Description: Comaprison between Drug Eluting and Bare Metal Coronary Stents
Study: NCT02832128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00063
Description: 4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 capsules of placebo, to take orally with food for 4 weeks
Study: NCT00955942

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01428453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250mg rilapladib
Description: Experimental Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator
Study: NCT01996709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide-based contact lens solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual contact lens solution
Description: Biguanide-preserved
Study: NCT02610491

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: Citrus peel extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose
Study: NCT01730404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001 DPI
Study: NCT02832128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 capsules of placebo, to take orally with food for 4 weeks
Study: NCT01996709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual contact lenses
Description: Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
Study: NCT02442960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal treatment (SA100)
Description: This treatment has been used extensively in traditional medicine practices for hundreds of years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal treatment (SA100)
Description: This treatment has been used extensively in traditional medicine practices for hundreds of years.
Study: NCT01817933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy
Study: NCT01641692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 Active treatment or Placebo
Description: Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 Active treatment or Placebo
Description: Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
Study: NCT01730404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Study: NCT01730404

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01641692

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 (Sub-group cohort)
Description: Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
Study: NCT06437626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexidol
Description: 50 mg/ml IV solution, 250 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV solution, Placebo tablets
Study: NCT01641692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
Study: NCT04536948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling Gel
Description: Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pack
Description: Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
Study: NCT01641692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
Study: NCT00859339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine ( 1000 mg/m2) IV days 1 and 8
Study: NCT01641692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
Study: NCT00859339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (70 mg/m2) IV day 1
Study: NCT01487954

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alkaline water
Description: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: distilled water
Description: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
Study: NCT00859339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Sunitinib malate (37.5 mg) oral daily for days 1-14

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
Study: NCT00750529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine and Donepezil
Description: the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
Study: NCT04234087

Intervention type: OTHER
Group type: OTHER
Intervention: Additional balance and resistance training
Description: Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
Study: NCT02387736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy-6 months
Description: Modification of behaviours achieved with reframing thoughts and impulses

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behaviour Therapy-12 months
Description: Modification of behaviours achieved with reframing thoughts and impulses
Study: NCT01909882

Intervention type: OTHER
Group type: OTHER
Intervention: Massage therapy
Description: One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
Study: NCT04268875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same.
Study: NCT04646161

Intervention type: DRUG
Intervention: Misoprostol
Description: misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
Study: NCT03727087

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study: NCT02194920

Intervention type: PROCEDURE
Intervention: Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue
Study: NCT04086797

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AE-103
Description: 1980 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01411358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-elderly aged between 18 and 60
Description: one dose of 0.5mL AdimFlu-S

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elderly aged over 60
Description: one dose of 0.5mL AdimFlu-S
Study: NCT03079401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPC; rexlemestrocel-L
Description: MPCs will be injected into the patient's myocardium during planned surgical procedures.
Study: NCT03963089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume_6mL/kg
Description: Set tidal volume to 6mL/kg for 1 minute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume_10mL/kg
Description: Set tidal volume to 10mL/kg for 1 minute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume_14mL/kg
Description: Set tidal volume to 10mL/kg for 1 minute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid loading
Description: Administer 10mL/kg of crystalloid for 5 minutes
Study: NCT01209663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Intermediate Care
Description: Comparison of postoperative Intermediate Care versus Ward Care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Intermediate Care
Description: Comparison of postoperative Intermediate Care versus Ward Care.
Study: NCT00495924

Intervention type: PROCEDURE
Intervention: Pancreatic resection (PD)
Description: PD is a standard therapeutic surgical procedure. No additional interventions are performed.
Study: NCT01599871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: theophylline
Description: theophylline 100 mg, twice at day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT03945487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cell
Description: Taken a dose of 1.0\*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive treatment
Description: 1. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~2. Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers).
Study: NCT00179400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02355119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study: NCT04123288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-709478
Description: 1 film-coated minitablet contains 2 mg of ACT-709478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT-709478
Description: 1 hard capsule contains 10 mg of ACT-709478.
Study: NCT01487954

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy (EBRT)
Description: Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy (EBRT)
Description: Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
Study: NCT03110653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)